Literature DB >> 29082468

Tau Diagnostics and Clinical Studies.

Illana Gozes1, Günter Höglinger2, James P Quinn3, Nigel M Hooper3, Kina Höglund4,5.   

Abstract

This short editorial provides our point of view of the first EURO TAU meeting focusing on tau diagnostics and clinical studies. We cover postmortem analyses toward the identification of new biomarkers, tau imaging as a diagnostic biomarker, cerebrospinal fluid (CSF) sampling with emphasis on tau fragments, blood tests and genetic evaluations for sporadic cases, treatment aspects, drug development and points for future developments toward disease modification of devastating tauopathies.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29082468     DOI: 10.1007/s12031-017-0983-0

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  90 in total

1.  Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.

Authors:  Serge Gauthier; Howard H Feldman; Lon S Schneider; Gordon K Wilcock; Giovanni B Frisoni; Jiri H Hardlund; Hans J Moebius; Peter Bentham; Karin A Kook; Damon J Wischik; Bjoern O Schelter; Charles S Davis; Roger T Staff; Luc Bracoud; Kohkan Shamsi; John M D Storey; Charles R Harrington; Claude M Wischik
Journal:  Lancet       Date:  2016-11-16       Impact factor: 79.321

Review 2.  Sexual divergence in activity-dependent neuroprotective protein impacting autism, schizophrenia, and Alzheimer's disease.

Authors:  Illana Gozes
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

3.  Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs).

Authors:  Abbas M Walji; Eric D Hostetler; Harold Selnick; Zhizhen Zeng; Patricia Miller; Idriss Bennacef; Cristian Salinas; Brett Connolly; Liza Gantert; Marie Holahan; Stacey O'Malley; Mona Purcell; Kerry Riffel; Jing Li; Jaume Balsells; Julie A OBrien; Stacey Melquist; Aileen Soriano; Xiaoping Zhang; Aimie Ogawa; Serena Xu; Elizabeth Joshi; Joseph Della Rocca; Fred J Hess; Joel Schachter; David Hesk; David Schenk; Arie Struyk; Kerim Babaoglu; Talakad G Lohith; Yaode Wang; Kun Yang; Jianmin Fu; Jeffrey L Evelhoch; Paul J Coleman
Journal:  J Med Chem       Date:  2016-05-05       Impact factor: 7.446

4.  Tau Proteins Cross the Blood-Brain Barrier.

Authors:  William A Banks; Andrej Kovac; Petra Majerova; Kristin M Bullock; Min Shi; Jing Zhang
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

5.  Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy.

Authors:  Dana Wagshal; Sethu Sankaranarayanan; Valerie Guss; Tracey Hall; Flora Berisha; Iryna Lobach; Anna Karydas; Lisa Voltarelli; Carole Scherling; Hilary Heuer; Maria Carmela Tartaglia; Zachary Miller; Giovanni Coppola; Michael Ahlijanian; Holly Soares; Joel H Kramer; Gil D Rabinovici; Howard J Rosen; Bruce L Miller; Jere Meredith; Adam L Boxer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-06-04       Impact factor: 10.154

6.  A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.

Authors:  Yasuji Matsuoka; Yan Jouroukhin; Audrey J Gray; Li Ma; Chiho Hirata-Fukae; Hui-Fang Li; Li Feng; Laurent Lecanu; Benjamin R Walker; Emmanuel Planel; Ottavio Arancio; Illana Gozes; Paul S Aisen
Journal:  J Pharmacol Exp Ther       Date:  2008-01-16       Impact factor: 4.030

Review 7.  A Review of Treatment Options for Progressive Supranuclear Palsy.

Authors:  Maria Stamelou; Günter Höglinger
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

8.  Tau and caspase 3 as targets for neuroprotection.

Authors:  Anat Idan-Feldman; Regina Ostritsky; Illana Gozes
Journal:  Int J Alzheimers Dis       Date:  2012-05-30

9.  Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.

Authors:  Jere E Meredith; Sethu Sankaranarayanan; Valerie Guss; Anthony J Lanzetti; Flora Berisha; Robert J Neely; J Randall Slemmon; Erik Portelius; Henrik Zetterberg; Kaj Blennow; Holly Soares; Michael Ahlijanian; Charles F Albright
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

10.  Plasma tau in Alzheimer disease.

Authors:  Niklas Mattsson; Henrik Zetterberg; Shorena Janelidze; Philip S Insel; Ulf Andreasson; Erik Stomrud; Sebastian Palmqvist; David Baker; Cristina A Tan Hehir; Andreas Jeromin; David Hanlon; Linan Song; Leslie M Shaw; John Q Trojanowski; Michael W Weiner; Oskar Hansson; Kaj Blennow
Journal:  Neurology       Date:  2016-09-30       Impact factor: 9.910

View more
  3 in total

1.  Vineland Adaptive Behavior Scale in a Cohort of Four ADNP Syndrome Patients Implicates Age-Dependent Developmental Delays with Increased Impact of Activities of Daily Living.

Authors:  Joseph Levine; Fahed Hakim; R Frank Kooy; Illana Gozes
Journal:  J Mol Neurosci       Date:  2022-08-03       Impact factor: 2.866

2.  EuroTau: towing scientists to tau without tautology.

Authors:  Amrit Mudher; Jean-Pierre Brion; Jesus Avila; Miguel Medina; Luc Buée
Journal:  Acta Neuropathol Commun       Date:  2017-11-29       Impact factor: 7.801

3.  NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies.

Authors:  Yanina Ivashko-Pachima; Maya Maor-Nof; Illana Gozes
Journal:  PLoS One       Date:  2019-03-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.